PEPITEM Peptide Bone Formation Stimulation
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current therapies for osteoporosis and bone-related diseases primarily focus on reducing bone resorption without effectively stimulating bone formation, leading to limitations in bone repair and remodeling, and are associated with side effects such as increased fracture risk and abnormal bone density.
Innovation Solution
Administration of a peptide with the amino acid sequence SVTEQGAELSNEER (PEPITEM) or its variants to patients and bone cells, which stimulates osteoblast activity and balances osteoclast and osteoblast activity to promote bone production and reduce bone loss.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Loss of substance
If anti-resorptive bisphosphonates are used to treat osteoporosis, then bone resorption is reduced, but bone formation is hindered and fracture risk increases
Solution Approach 1:
Instead of only inhibiting bone resorption (conventional approach), the patent applies inversion by simultaneously stimulating bone formation through peptide administration. This dual-action approach reverses the imbalance caused by conventional therapies, promoting both bone production and reduced resorption to improve overall bone strength.
Solution Approach 2:
The patent changes the therapeutic parameter from single-target inhibition (bisphosphonates targeting osteoclasts) to dual-target modulation (peptide targeting both osteoblasts and osteoclasts). This parameter change enables simultaneous enhancement of bone formation and inhibition of resorption, resolving the contradiction between reducing bone loss and maintaining bone strength.
2Loss of substance
If anti-RANKL antibody (denosumab) is used, then bone resorption is reduced, but bone formation is not affected
Solution Approach 1:
The patent merges the functions of bone resorption inhibition and bone formation stimulation into a single therapeutic approach. The peptide compound simultaneously targets both osteoclasts (to reduce resorption) and osteoblasts (to enhance formation), combining two previously separate therapeutic actions into one integrated treatment.
Solution Approach 2:
The peptide compound exhibits multi-functionality by acting on both osteoclasts and osteoblasts. This universal approach allows a single agent to perform multiple functions: inhibiting bone resorption while simultaneously stimulating bone formation, thereby addressing both aspects of bone health rather than treating them separately.
3Loss of substance
If cathespin K inhibitor (odanacatib) is used, then bone resorption is reduced, but stroke risk increases
Solution Approach 1:
The patent introduces a peptide compound as an intermediary therapeutic agent that mediates between bone resorption inhibition and bone formation stimulation. This intermediary approach allows reduction of bone loss while avoiding the severe side effects (such as stroke risk) associated with direct cathespin K inhibition, by using a more balanced dual-action mechanism.
4Object-affected harmful factors
If existing therapies focus on reducing joint pain and slowing bone damage, then symptom relief is achieved, but bone repair and remodeling are not effectively stimulated
Solution Approach 1:
The patent applies preliminary action by stimulating bone formation before and during the repair process. Instead of only providing symptomatic relief and slowing damage, the peptide therapy proactively promotes bone production and remodeling activities, preparing and supporting the bone repair process rather than merely preventing deterioration.
Data Source
AI summary
The present invention concerns methods of reducing bone loss and/or stimulating bone production comprising administering an effective amount of a peptide comprising the amino acid sequence SVTEQGAELSNEER (SEQ ID NO:1), or variants thereof, to a patient and/or bone cells. The present invention also concerns methods of treatment and/or prophylaxis of musculoskeletal loss and/or damage in a patient, comprising administering an effective amount of the peptide.